Neurology · 1977 · 32 citations · 0 references
MedicineNeurologyPharmacotherapyNeuromuscular DisordersIdiopathic Inflammatory MyopathiesMuscle DisordersMuscle WeaknessNeuromuscular Disorder PharmacotherapyNeuromuscular PhysiologyNeuromuscular RehabilitationFacioscapulohumeral Myopathy EvaluationImmune-mediated MyopathiesInflammatory Myopathy PharmacotherapyMuscle DamageSerum Creatine Kinase AssessmentTherapeutic Benefit-risk AssessmentTherapeutic Risk-benefit Assessment
Evidence is cited from the literature and from personal experience with the "inflammatory" form of facioscapulohumeral syndrome that the creatine phosphokinase reduction occurring during pharmacologic treatment of various neuromuscular diseases does not necessarily imply therapeutic benefit.